BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Yuan F, Liu N, Yang MZ, Zhang XT, Luo H, Zhou H. Circulating tumor DNA genomic profiling reveals the complicated olaparib-resistance mechanism in prostate cancer salvage therapy: A case report. World J Clin Cases 2022; 10(11): 3461-3471 [PMID: 35611209 DOI: 10.12998/wjcc.v10.i11.3461]
URL: https://www.wjgnet.com/2307-8960/full/v10/i11/3461.htm
Number Citing Articles
1
Abiraterone/docetaxel/olaparibReactions Weekly 2022; 1908(1): 16 doi: 10.1007/s40278-022-15744-6
2
Marta Lopez-Valcarcel. Liquid biopsy to personalize treatment for metastatic prostate cancerAmerican Journal of Translational Research 2024; 16(5): 1531 doi: 10.62347/DICU9510
3
Wei He, Yutian Xiao, Shi Yan, Yasheng Zhu, Shancheng Ren. Cell-free DNA in the management of prostate cancer: Current status and future prospectiveAsian Journal of Urology 2023; 10(3): 298 doi: 10.1016/j.ajur.2022.11.002